Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs

Transplantation

Volumn 75, Issue 8, 2003, Pages 1128-1133

  Kyles, Andrew E ^a   Gregory, Clare R ^a   Griffey, Stephen M ^a   Bernsteen, Lynda ^a   Pierce, Jon ^b   Lilja, Herman S ^c   Morris, Randall E ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METOCLOPRAMIDE; MISOPROSTOL; UNCLASSIFIED DRUG;

ANIMAL MODEL; CONFERENCE PAPER; DIARRHEA; DOG; DRUG BLOOD LEVEL; DRUG POTENTIATION; GASTRITIS; GRAFT SURVIVAL; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE INTUSSUSCEPTION; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; VOMITING;

ALKYNES; ANIMALS; CYCLOSPORINE; DOGS; DRUG THERAPY, COMBINATION; EMULSIONS; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; KIDNEY; KIDNEY TRANSPLANTATION; NITRILES; OSMOLAR CONCENTRATION;

EID: 0037469015     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000061789.97072.12     Document Type: Conference Paper

References (32)

1. Kurrle R, Ruuth E, Bartlett R, et al. Malononitrilamides inhibit T- and B-cell responsiveness in different species. Transplant Proc 1997; 29: 1302.
2. Slauson SD, Silva HT, Sherwood SW, et al. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. Immunol Lett 1999; 67: 179.
3. Silva HT, Morris RE, Leflunomide and malononitrilamides. Am J Med Sci 1997; 313: 289.
4. Gerauer K, Maier S, Emmanuilidis K, et al. Long-term cardiac allograft survival in mice treated with malononitrilamide 715. Transplant Proc 1998; 30: 4205.
5. Lindner JK, Zantl N. Synergism of the malononitrilamides 279 and 715 with cyclosporin A in the induction of long-term cardiac allograft survival. Transpl Int 1998; 11: S303.
6. Qi Z, Simanaitis M, Ekberg H. Malononitrilamides 715 and 279 prevent accelerated cardiac allograft rejection synergistically with cyclosporin A in presensitized rats. Transplant Immunol 1998; 6: 94.
7. Schorlemmer HU, Ruuth E, Kurrle R. Malononitrilamides synergistically prevent acute and treat ongoing skin allograft rejection with cyclosporine. Transpl Int 1998; 11: S340.
8. Schorlemmer HU, Kurrle R, Bartlett RR. Malononitrilamides inhibit the development of various murine graft-vs-host diseases. Transplant Proc 1996; 28: 3043.
9. Schorlemmer HU, Kurrle R. Synergistic activity of malononitrilamides with cyclosporine to control and reverse xenograft rejection. Int J Tissue React 1997; 19: 149.
10. Lin Y, Segers C, Waer M. Efficacy of the malononitrilamide X 920715 as compared with leflunomide in cardiac allo- and xenotransplantation in rats. Transplant Proc 1996; 28: 3036,
11. Vriens PW, Pollard JD, Hoyt GG, et al. Hamster cardiac xenografts are protected against antibody mediated damage early after transplantation to Lewis rats. Xenotransplantation 2001; 8: 239.
12. Chong AS, Rezai K, Gebel HM, et al. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 1996; 61: 140.
13. McChesney LP, Xiao F, Sankary HN, et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994; 57: 1717.
14. Lirtzman RA, Gregory CR, Levitski RE, et al. Combined immunosuppression with leflunomide and cyclosporine prevents MLR-mismatched renal allograft rejection in a mongrel canine model. Transplant Proc 1996; 28: 945.
15. Kyles AE, Gregory CR, Griffey SM, et al. An evaluation of combined immunosuppression with MNA 715 and microemulsified cyclosporine on renal allograft rejection in outbred mongrel dogs. Vet Surg 2002; 31: 358.
16. Oakes MG, Lewis DD, Hosgood G, et al. Enteroplication for the prevention of intussusception recurrence in dogs: 31 cases (1978-1992). J Am Vet Med Assoc 1994; 205: 72.
17. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
18. Caridis DT, Liegeois A, Barrett I, et al. Enhanced survival of canine renal allografts of ALS-treated dogs given bone marrow. Transplant Proc 1973; 1: 671.
19. Platz KP, Sollinger HW, Hullett DA, et al. RS-61443: a new, potent immunosuppressive agent, Transplantation 1991; 51: 27.
20. Keown P, Landsberg D, Halloran P, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1996; 62; 1744.
21. Kelly GE, Drummond JM, Rogers JH, et al. Intussusception in dogs following renal homograft transplantation. Aust Vet J 1971; 47: 597.
22. McAnulty JF, Southard JH, Belzer FO. Prevention of postoperative intestinal intussusception by prophylactic morphine administration in dogs used for organ transplantation research, Surgery 1989; 105: 494.
23. Graves GM, Becht JL, Rawlings CA. Metoclopramide reversal of decreased gastrointestinal myoelectric and contractile activity in a model of canine postoperative ileus. Vet Surg 1989; 18: 27.
24. Childs WA, Phillips RB. Experience with intestinal plication and proposed modification. Ann Surg 1960; 152: 258.
25. Emre S, Sumrani N, Youngelman D, et al. Orthotopic hepatic transplantation in the dog. J Invest Surg 1992; 5: 51.
26. Noble TB. Plication of small intestine as prophylaxis against adhesions. Am J Surg 1937; 35: 441.
27. Ochiai T, Nagata M, Nakajima K, et al. Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation 1987; 44: 729.
28. Ochiai T, Sakamoto K, Gunji Y, et al. Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs, Transplantation 1989; 48: 193.
29. Ochiai T, Gunji Y, Nagata M, et al. Effective and safe use of FK 506 combination treatment with rapamycin or RS-61443 in experimental organ transplantation. Transplant Proc 1991; 23: 2718.
30. Ochiai T, Gunji Y, Nagata M, et al. Effects of rapamycin in experimental organ allografting. Transplantation 1993; 6: 15.
31. Thiru S, Collier DS, Calne R. Pathological studies in canine and baboon allograft recipients immunosuppressed with FK-506. Transplant Proc 1987; 19(suppl 6): 98-99.
32. Todo S, Ueda Y, Demetris JA, et al. Immunosuppression of canine, monkey, and baboon allografts by FK506: with special reference to synergism with other drugs and to tolerance induction. Surgery 1988; 104: 239.